¾ÅÖÝÓ°Ôº

Introduction

Theme 1: Design & Development of NK-Based Therapies

• Increasing the safety and persistence of allogeneic NK therapies 
• Genetic modification of NK cells to retarget and sustain anti-tumour activity 
• In vitro approaches to accelerate off-target effect & toxicity research 
• Leveraging mechanism of action to elicit stronger & safer therapeutic activity 
• Optimised analytical approaches tailored to NK-based therapies 

Theme 2: Application of NK-Based Therapies

• Utilising the most effective strategy for solid tumours 
• Harnessing NK cell memory for leukaemia immunotherapy 
• Case studies of NK & CAR-NK clinical trials for haematological malignancies 
• Strategies for combining NK cells with other agents 

 

Useful links

Speakers

• Jan Spanholtz Glycostem, Germany
• Marcela Guzman Senti Biosciences, United States
• Aviad Pato Gamida Cell, Israel
• Shawn Cogan Takeda, United States
• Björn Önfelt KTH Royal Institute of Technology, Sweden

---

Venue

Virtual Event

Virtual Event, online, Virtual Event, Virtual, United Kingdom

Committee

• Oxford Global United Kingdom

---

Organised by

Oxford Global

Contact information

Bronwyn Westmore
Oxford Global
Contact us by email

---